A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial

OBJECTIVE: Pharmacogenomic-based antidepressant treatment (PGATx) may result in more precise pharmacotherapy of major depressive disorder (MDD) with better drug therapy guidance. METHODS: An 8-week, randomized, single-blind clinical trial was conducted to evaluate the effectiveness and tolerability...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Changsu, Wang, Sheng-Min, Bahk, Won-Myong, Lee, Soo-Jung, Patkar, Ashwin A., Masand, Prakash S., Mandelli, Laura, Pae, Chi-Un, Serretti, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245286/
https://www.ncbi.nlm.nih.gov/pubmed/30466219
http://dx.doi.org/10.9758/cpn.2018.16.4.469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245286/
https://www.ncbi.nlm.nih.gov/pubmed/30466219
http://dx.doi.org/10.9758/cpn.2018.16.4.469

Ejemplares similares